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Simple Summary: The necessity of completion total thyroidectomy is unclear in patients with
papillary thyroid microcarcinoma (PTMC) with only pathological central lymph node metastasis
(pCLNM). The aim of our study was to determine the necessity of completion total thyroidectomy after
an initial surgery by comparing the prognosis according to the presence of pCLNM during a long-term
follow-up. We retrospectively compared the pathological central lymph node (pCLN)-positive group
of 165 patients who underwent thyroid lobectomy with the pCLN-negative group of 711 patients
and found no difference between the two groups in the recurrence rate and disease-free survival
rates. Therefore, PTMC patients who underwent thyroid lobectomy with prophylactic central
compartment neck dissection and were diagnosed with pCLNM after surgery do not require
completion total thyroidectomy.
Abstract: The necessity of completion total thyroidectomy in patients with papillary thyroid
microcarcinoma (PTMC) and pathological central lymph node metastasis (pCLNM) who underwent
thyroid lobectomy with central compartment neck dissection (CCND) is unclear. We determined the
necessity of completion total thyroidectomy by retrospectively comparing the prognosis according to
the presence of pCLNM during a long-term follow-up. We enrolled 876 patients with PTMC who
underwent thyroid lobectomy with prophylactic CCND from January 1986 to December 2009. Patients
were divided according to central lymph node (CLN) metastasis: 165 (18.8%) and 711 (81.2%) in the
CLN-positive and CLN-negative groups, respectively. Medical records were reviewed retrospectively,
and clinicopathologic characteristics and recurrence rates were analyzed. The CLN-positive group
was associated with male sex (p = 0.001), larger tumor size (p < 0.001), and more microscopic capsular
invasion (p < 0.001) compared with the CLN-negative group. There was no significant difference
between the two groups’ recurrence (p = 0.133) or disease-free (p = 0.065) survival rates. Univariate
and multivariate analyses showed no factors associated with tumor recurrence except male sex
(hazard ratio = 3.043, confidence interval 1.117–8.288, p = 0.030). Patients who were diagnosed with
pCLNM after undergoing thyroid lobectomy with prophylactic CCND do not require completion
total thyroidectomy; however, frequent follow-up is necessary for patients with PTMC and pCLNM.
Keywords: papillary thyroid microcarcinoma; completion total thyroidectomy; central lymph node
metastasis; recurrence
Cancers 2020, 12, 3032; doi:10.3390/cancers12103032 www.mdpi.com/journal/cancers
Cancers 2020, 12, 3032 2 of 12
1. Introduction
Thyroid cancer (TC) is an increasingly common malignancy, of which papillary thyroid cancer (PTC)
is the most common histologic type, with a reported incidence of 80% to 85% [1,2]. Papillary thyroid
microcarcinoma (PTMC) is defined as a tumor less than 1 cm in size and has a good prognosis, with a
10-year survival rate over 95% and a recurrence rate of 10% [3–5]. Central lymph node (CLN) metastasis
has been reported in 20.7–62% of clinically lymph node negative (cN0) PTMC cases [6–10]. Previous studies
reported that CLN metastasis was associated with recurrence [11–14]. Although patients with CLN
metastasis have a risk of recurrence, the effectiveness of completion total thyroidectomy in patients
diagnosed with pathological CLN metastasis (pCLNM) after surgery is still controversial. According to
the 2015 American Thyroid Association (ATA) guidelines, completion total thyroidectomy is necessary in
cases of unclear diagnosis after lobectomy, to provide complete resection of multicentric disease, and to
allow for efficient radioactive iodine (RAI) therapy; however, the guidelines do not specify pCLNM [15].
Prophylactic central compartment neck dissection (CCND) can affect the pCLNM rate. The mean
size and number of metastatic lymph nodes removed during prophylactic CCND were reported as
0.35 cm and 2.6 ± 3 out of 13 ± 5 lymph nodes, respectively [16,17]. As pCLNM was reported to be a
micrometastasis, performing prophylactic CCND in patients with cN0 PTMC has been continually
under controversy. Multiple studies have compared thyroidectomy alone to thyroidectomy with
CCND in cN0 PTMC and reported varying results in complications, recurrence rates, and patient
prognosis [18–20]. Although opinions vary, most head and neck surgeons and endocrine surgeons in
Korea, China, and Japan perform prophylactic CCND even in cases of cN0 PTMC.
Our previous study demonstrated that there was no significant difference in prognosis between
CLN-positive and CLN-negative patients with PTMC [21]. As the number of patients with recurrence
in the previous study was small, it is necessary to confirm the benefit of completion total thyroidectomy
in a CLN-positive group based on more cases and long-term observation. This retrospective study was
designed to evaluate the necessity of completion total thyroidectomy in low-risk PTMC patients with
pCLNM who underwent thyroid lobectomy with prophylactic CCND at a single medical center.
2. Results
2.1. Characteristics of the Two Groups
The CLN-positive group showed a greater association with male sex (19.4% vs. 10.4%, p = 0.001),
a larger tumor size (0.59 ± 0.23 vs. 0.52 ± 0.23, p < 0.001), and more microscopic capsular invasion
(42.4% vs. 26.6%, p < 0.001) than the CLN-negative group. The mean follow-up duration for the
CLN-positive and CLN-negative groups was 12.8 ± 4.3 years (range 8.3 to 30.5) and 13.4 ± 4.4 years
(range 8.3 to 32.3), respectively. The recurrence rates for the CLN-positive and CLN-negative groups
were 7.9% and 4.9%, respectively, but there was no statistically significant difference between the
groups. There was no mortality in either the CLN-positive group or the CLN-negative group (Table 1).
Table 1. Clinicopathologic characteristics of the central lymph node (CLN)-positive and CLN-negative groups.
Characteristics CLN-Positive (n = 165) CLN-Negative (n = 711) p-Value
Sex 0.001
Female 133 (80.6%) 637 (89.6%)
Male 32 (19.4%) 74 (10.4%)
Age (years) 0.355
<55 148 (89.7%) 619 (87.1%)
≥55 17 (10.3%) 92 (12.9%)
Tumor size (cm) 0.59 ± 0.23 0.52 ± 0.23 <0.001
Microscopic capsular invasion 70 (42.4%) 189 (26.6%) <0.001
Multifocality 18 (10.9%) 77 (10.8%) 0.976
Recurrence 13 (7.9%) 35 (4.9%) 0.133
Mean follow-up duration (years) 12.8 ± 4.3 13.4 ± 4.4 0.166
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2.2. Recurrence in the Two Groups
Thirteen patients (7.9%) in the CLN-positive group experienced recurrence during the follow-up
period. Six had recurrence in the contralateral lobe, two in both the contralateral lobe and the lateral
lymph node (LN), and five in the lateral LN. In the CLN-negative group, 35 (4.9%) patients experienced
recurrence. Twenty-seven had recurrence in the contralateral lobe, two in both the contralateral lobe
and the lateral LN, and six in the lateral LN. There was no operative bed, central neck, or distant
recurrence (Figure 1).
Cancers 2020, 12, x 3 of 13 
 
Tumor size (cm) 0.59 ± 0.23 0.52 ± 0.23 <0.001 
Microscopic capsular invasion 70 (42.4%) 189 (26.6%) <0.001 
Multifocality 18 (10.9%) 77 (10.8%) 0.976 
Recurrence 13 (7.9%) 35 (4.9%) 0.133 
Mean follow-up duration (years) 12.8 ± 4.3 13.4 ± 4.4 0.166 
2.2. Recurrence in the Two Groups 
Thirteen patients (7.9%) in the CLN-positive group experienced recurrence during the follow-
up period. Six had recurrence in the contralateral lobe, two in both the contralateral lobe and the 
lateral lymph node (LN), and five in the lateral LN. In the CLN-negative group, 35 (4.9%) patients 
experienced recurrence. Twenty-seven had r currence in the contralateral lobe, two in both the 
contralateral lobe and the lateral LN, nd six in the lateral LN. There was no operative bed, central 
neck, or distant recurrence (Figure 1). 
 
Figure 1. Recurrence in the CLN-positive and CLN-negative groups. Abbreviations: CLN: Central 
lymph node; LN: Lymph node; pts: Patients. 
The univariate and multivariate analysis showed that there were no factors associated with 
tumor recurrence except male sex (hazard ratio [HR] = 3.043, 95% confidence interval [CI] 1.117-8.288, 
p = 0.030) (Table 2). The 10- and 20-year disease-free survival (DFS) rates for the CLN-positive and 
CLN-negative groups were 99.1% vs. 99.7% and 78.0% vs. 88.9%, respectively (Figure 2). There was 
no significant difference in DFS rates between the two groups (p = 0.065). 
Figure 1. Recurrence in the CLN-positive and CLN-negative groups. Abbreviations: CLN: Central
lymph node; LN: ymph node; pts: Patients.
The univar ate nd multivariate analysis s that there w re no factor associated with
tumor recurrence except male s x (hazard ratio [ 3.043, 95% confidence interval [CI] 1.117-8.288,
p = 0.030) (Table 2). The 10- and 20-year disease-free s rvival (DFS) rates for the CLN-positive and
CLN-negative groups were 99.1% vs. 99.7% and 78.0% vs. 88.9%, respectively (Figure 2). There was no
significant difference in DFS rates between the two groups (p = 0.065).
Table 2. Cox proportional hazard analysis of variables predicting recurrence after less than total thyroidectomy.
Variable N Recurrence Univariate Analysis Multivariate Analysis
HR (95% CI) p-Value HR (95% CI) p-Value
Sex 0.016 0.030
Female 770 43 (5.6%) 1.000 1.000
Male 106 5 (4.7%) 3.307 (1.245–8.787) 3.043 (1.117–8.288)
Age (years) 0.154 0.194
<55 767 42 (5.5%) 1.000 1.000
≥55 109 6 (5.5%) 1.887 (0.788–4.523) 1.793 (0.743–4.326)
Tumor size 0.456 0.732
≤5 mm 505 19 (3.8%) 1.000 1.000
>5 mm 371 29 (7.8%) 1.254 (0.691–2.276) 1.119 (0.587–2.133)
Multifocality 0.184 0.243
Absent 781 42 (5.4%) 1.000 1.000
Present 95 6 (6.3%) 1.844 (0.773–4.400) 1.700 (0.698–4.143)
Microscopic capsular invasion 0.262 0.540
Absent 617 33 (5.3%) 1.000 1.000
Present 259 15 (5.8%) 1.432 (0.765–2.680) 1.242 (0.621–2.484)
CLN metastasis 0.069 0.123
Absent 711 35 (4.9%) 1.000 1.000
Present 165 13 (7.9%) 1.815 (0.954–3.452) 1.687 (0.868–3.275)
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with male sex (HR = 7.113, CI 1.708–29.622, p = 0.007), tumor size over 5 mm (HR = 3.790, CI 1.009–14.236,
p = 0.048), and CLN metastasis (HR = 3.649, CI 1.192–11.169, p = 0.023) (Table 3).
Table 3. Cox proportional hazard analysis of variables predicting recurrence of lateral neck lymph
nodes after less than total thyroidectomy.
Variable N Lateral LNRecurrence Univariate Analysis Multivariate Analysis
HR (95% CI) p-Value HR (95% CI) p-Value
Sex <0.001 0.007
Female 770 11 (1.4%) 1.000 1.000
Male 106 4 (3.8%) 10.620(2.833–39.808) 7.113 (1.708–29.622)
Age (years) 0.087 0.090
<55 767 12 (1.6%) 1.000 1. 00
≥55 109 3 (2.8%) 3.121 (0.848–11.483) 3.190 (0.835–12.184)
Tumor size 0.055 0.048
≤5 mm 505 3 (0.6%) 1.000 1.000
>5 mm 371 12 (3.2%) 3.515 (0.975–12.675) 3.790 (1.009–14.236)
Multifocality 0.407 0.375
Absent 781 13 (1.7%) 1.000 1.000
Present 95 2 (2.1%) 1.895 (0.418–8.595) 2.023 (0.427–9.591)
Microscopic capsular invasion 0.938 0.444
Absent 617 11 (1.8%) 1.000 1.000
Present 259 4 (1.5%) 1.047 (0.327–3.348) 0.616 (0.178–2.134)
CLN metastasis 0.007 0.023
Abs nt 711 8 (1.1%) 1.000 1.000
Present 165 7 (4.2%) 4.064 (1.463–11.292) 3.649 (1.192–11.169)
2.3. Postoperative Complications in the Two Groups
Seven (4.2%) patients experienced postoperative complications in the CLN-positive group and 37
(5.2%) experienced postoperative complications in the CLN-negative group (p = 0.519). There was
no significant difference between the two groups in postoperative complications, except recurrent
laryngeal nerve (RLN) injury. The rate of RLN injury was higher in the CLN-positive group than in the
CLN-negative group (1.8% vs. 0.1%, p = 0.023) (Table 4).
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Table 4. Postoperative complications of the CLN-positive and CLN-negative groups.
Complications CLN Positive (n = 165) CLN Negative (n = 711) p-Value
Complication 0.519
Absent 158 (95.8%) 674 (94.8%)
Present 7 (4.2%) 37 (5.2%)
Hematoma 1.000
Absent 165 (100%) 710 (99.9%)
Present 0 (0%) 1 (0.1%)
Seroma 0.331
Absent 164 (99.4%) 696 (97.9%)
Present 1 (0.6%) 15 (2.1%)
Hoarseness (transient) 1.000
Absent 163 (98.8%) 701 (98.6%)
Present 2 (1.2%) 10 (1.4%)
Hypocalcemia (transient) 0.700
Absent 164 (99.4%) 701 (98.6%)
Present 1 (0.6%) 10 (1.4%)
RLN injury 0.023
Absent 162 (98.2%) 710 (99.9%)
Present 3 (1.8%) 1 (0.1%)
2.4. Comparison Characteristics of the Enrolled Patients in Two Periods
We analyzed the characteristics of the enrolled patients by dividing the period into two parts to
compare the older results and recent results: First period, 1986–1997; second period, 1998–2009. The first
period consisted of 46 patients. Eight hundred and thirty patients were in the second period. There was
no significant difference between the two periods in microscopic capsular invasion, multifocality,
CLN metastasis, or complications. Recurrence rate was higher in the first period (19.6% vs. 4.7%,
p < 0.001), but there was no significant difference between the two periods in mean recurrence-free
survival duration (Table 5).
Table 5. Comparison characteristics of the enrolled patients in two periods.
Characteristics First Period1986–1997 (n = 46)
Second Period
1998–2009 (n = 830) p-Value
Sex 0.010
Female 46 (100%) 724 (87.2%)
Male 0 (0%) 106 (12.8%)
Age (years) 0.030
<55 45 (97.8%) 722 (87.0%)
≥55 1 (2.2%) 108 (13.0%)
Tumor size (cm) 0.63 ± 0.30 0.53 ± 0.23 0.020
Microscopic capsular invasion 10 (21.7%) 249 (30.0%) 0.232
Multifocality 2 (4.3%) 93 (11.2%) 0.219
CLN metastasis 8 (17.4%) 157 (18.9%) 0.797
Complication 1 (2.2%) 43 (5.2%) 0.723
Hematoma 0 (0%) 1 (0.1%) 1.000
Seroma 0 (0%) 16 (1.9%) 1.000
Hoarseness (transient) 0 (0%) 12 (1.4%) 1.000
Hypocalcemia (transient) 1 (2.2%) 10 (1.2%) 0.449
RLN injury 0 (0%) 4 (0.5%) 1.000
Mean follow-up duration (years) 24.2 ± 2.4 12.7 ± 3.6 <0.001
Recurrence 9 (19.6%) 39 (4.7%) <0.001
Recurrence-free survival duration
≤5 years 3 (6.5%) 16 (1.9%) 0.073
>5 years 6 (13.0%) 23 (2.8%) 0.003
Mean recurrence-free survival
duration (years) 7.4 ± 3.4 5.7 ± 3.6 0.227
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3. Discussion
As the incidence of TC increases worldwide, the physicians’ interest in its treatment and prognosis
is increasing [22,23]. The long-term recurrence and mortality rates of PTMC are low; thus, there has
been constant controversy with regard to the definite treatment guidelines for TC [24,25]. Ito et al.
suggested active surveillance (AS) as a therapeutic option for low-risk PTMC [26]. AS can help reduce
the risk of surgical complications by avoiding immediate surgery, reducing costs, and improving
the quality of life [27,28]. However, the tumor progressed unexpectedly in about 2–15% of patients
who were considered suitable for AS, delaying treatment, and these patients’ cancer eventually
progressed to an aggressive disease [29–33]. According to previous studies, it was reported that the
loco-regional recurrence rate of patients who underwent lobectomy because of PTMC was 2–6%,
the distant metastasis rate was 1–2%, and the disease-specific mortality rate was less than 1% [34,35].
Since the clinical characteristics or molecular factors that distinguish low-risk PTMC patients at risk
of progression have not been clearly identified, whether surgery or AS has a therapeutic advantage
remains controversial.
Since pCLNM had been reported to be relatively high in PTMC, the presence or absence of
pCLNM may be estimated as a factor that can affect prognosis and treatment [36,37]. Completion
total thyroidectomy was recommended for an unclear diagnosis after lobectomy, complete resection of
multicentric disease, and efficient RAI therapy in the 2015 ATA guidelines [15]. However, there is little
information on the effectiveness of completion total thyroidectomy in patients who were diagnosed as
having pCLNM after thyroid lobectomy.
To demonstrate the usefulness of completion total thyroidectomy in patients diagnosed as having
pCLNM after surgery, we followed up low-risk PTMC patients who had undergone thyroid lobectomy
with prophylactic CCND for a long time period. During the 13 years of follow-up, 48 patients (5.5%)
experienced recurrence. The recurrence rate of the CLN-positive group was higher than that of the
CLN-negative group, but there was no significant between-group difference. Our multivariate analysis
showed that pCLNM was not associated with recurrence, and DFS was not significantly different
between the two groups. Furthermore, there was no distant metastasis or disease-specific mortality.
The recurrence rate of PTMC was reported to be 1.96–6% in previous studies. The most common
recurrence site was the contralateral lobe, followed by the lateral LN [25,38–43]. In our study, 33 patients
(33/48, 68.8%) experienced recurrence only in the contralateral lobe and 11 patients (11/48, 22.9%) only
in the lateral LN.
Since the most common recurrence site of PTMC was the contralateral lobe, we were faced with a
dilemma of whether to perform completion total thyroidectomy. Several studies have reported that
2–7% of patients experience transient recurrent laryngeal nerve (RLN) palsy; 0.5–4.4%, permanent
RLN palsy; 7–20%, transient hypoparathyroidism; and 2.5–5.8%, permanent hypoparathyroidism after
completion total thyroidectomy [44–47]. Although the incidence of complications is low, the risk of
complications can be completely circumvented by avoiding unnecessary surgery. In addition, because
there was no significant difference in long-term prognosis between the CLN-positive and CLN-negative
groups and the recurrence rate was very low, we could suggest that completion total thyroidectomy in
PTMC with pCLNM was not necessary.
An additional consideration is that pCLNM can affect lateral LN recurrence. Several previous
studies have revealed that pCLNM is associated with lateral LN metastasis [37,48–51]. These studies
indicated the possibility of occult lateral LN metastasis in TC with pCLNM. However, there were
few studies that proved the relationship between pCLNM and lateral LN recurrence of PTMC after
long-term follow up. Ryu et al. reported that the pCLNM rate of TC patients who underwent total
thyroidectomy was 33.2%, and lateral LN recurrence was associated with pCLNM [52]. Our analysis
showed similar results. Lateral LN recurrence in the CLN-positive group was significantly higher than
in the CLN-negative group (odds ratio = 3.893, CI 1.391–10.894, p = 0.012). The multivariate analysis
found that lateral LN recurrence was associated with male sex, tumor size over 5 mm, and pCLNM.
Although pCLNM can develop into lateral LN recurrence, the lateral recurrence rate was very low
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(7/165, 4.2%). Therefore, active and frequent follow-up is thought to be sufficient for patients with
pCLNM. In addition, lateral LN metastasis without pCLNM, so-called skip metastasis, was reported in
6.8–27.8% of PTC patients [48,53–57]. Combining this finding with our results, we carefully question
the effectiveness of prophylactic CCND for cN0 PTMC; however, additional prospective randomized
studies will be needed in the future.
In several previous studies, the complication rate after thyroidectomy was reported in 5.1% to
26.0% of cases [58–60]. Our study showed a relatively low complication rate (44/876, 5.0%). In particular,
the rate of hypocalcemia occurrence was 1.3% (11/876) and RLN injury was 0.4% (4/876), which were
very low. This result was likely due to the fact that our institution is a high-volume center where
specialized endocrine surgeons perform thyroidectomy. Previous studies showing that high volume
surgeons had better outcomes relating to complications and prognosis support this [58–62]. Therefore,
we can suggest that experienced, specialized endocrine surgeons play a significant part in reducing
surgical complications.
Our research showed that the rate of RLN injury was higher in the CLN-positive group.
Postoperative complications can occur in any surgery. Since our hospital is an academic institution,
trainees frequently participate in surgeries. Although the number of RLN injuries was very small,
they did occur. It is difficult to explain why RLN injuries occurred more frequently in the CLN-positive
group. Since the surgical range of both groups was determined under the same pre-surgical conditions
and indications, we do not think that microscopic CLN metastasis affected the occurrence of surgical
complications. According to previous studies, there was no significant difference in complication and
clinical outcome when trainees participated in surgery [63–66]. Therefore, we do not believe that the
involvement of trainees influenced the RLN injury rate.
When the patients were divided into two periods and analyzed, the recurrence rate of the patients
in the first period was significantly higher. However, this may be the result of the significant difference
between the two periods in mean follow-up duration (24.2 ± 2.4 vs. 12.7 ± 3.6, p < 0.001). Furthermore,
since there was no difference in the mean recurrence-free survival duration, we believe that the
difference in recurrence rates between the two periods would not have a significant effect on our
study’s results.
There are some limitations to this study. First, as the quality of ultrasonography was not good
in the 1980s and 1990s, it could not detect very tiny nodules, which may have been mistaken for
recurrence at a later time point. This may have affected the recurrence rate of patients. In our subgroup
analysis by period, the fact that the rate of recurrence 5 years after surgery was significantly higher in
the first period indicates this possibility (13.0% vs. 2.8%, p = 0.003). However, since the number of
recurrence patients in the first period was very small, further research is needed. Second, incidental
multifocality or microscopic extrathyroidal extension that was undetectable before surgery could
have affected the recurrence rates, although multivariate analysis revealed that the two factors were
not related to recurrence rates. Third, recent studies have shown that BRAFV600E or TERT promoter
mutations could affect aggressive features and the prognosis of PTC [67–69]. However, the effects of
BRAFV600E or TERT promoter mutations on prognosis could not be analyzed in this study because of
limited data. Additional research is needed on this in the future.
4. Materials and Methods
4.1. Ethics Statement
Severance Hospital Institutional Review Board (IRB) gave permission to conduct this study
(IRB approval number: 4-2020-0270). Obtaining written informed consent from patients was waived
by our ethics committee.
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4.2. Patients
We retrospectively reviewed the records of 11,336 PTC patients from January 1986 to December
2009. During this period, our institution performed surgeries similar to that described in the 2006
and 2009 ATA guidelines. When the lesion was smaller than 1 cm, unilateral, intrathyroidal, or
cN0 thyroid lobectomy with prophylactic CCND was performed, and all other patients underwent
bilateral total thyroidectomy with CCND. All patients underwent prophylactic ipsilateral CCND,
including the prelaryngeal, pretracheal, and paratracheal LN. Among them, 1209 PTMC patients
underwent thyroid lobectomy with prophylactic CCND. On preoperative evaluation, all these patients
were diagnosed to not have CLN metastases. In our previous study, 281 patients with PTMC from
January 1986 to December 2001 were enrolled. Of them, 185 patients were completely followed up
and 691 patients were newly added in this study. Overall, 333 of 1209 patients failed to follow up,
and 876 patients were followed up completely. Microscopic capsular invasion was defined as capsule
invasion confirmed by a microscope in the final pathologic result. Multifocality was defined as two or
more cancer foci in the same lobe. Recurrence was determined when a newly discovered lesion using
ultrasonography was confirmed as cancer by a fine needle aspiration biopsy during postoperative
follow-up. Clinicopathologic characteristics of the enrolled patients are summarized in Table 6.
Table 6. Clinicopathologic characteristics of enrolled patients.




















Mean follow-up duration (years) 13.3 ± 4.4
Patients were divided into two groups according to the presence of CLN metastasis in the final
pathology results: The CLN-positive group and CLN-negative group. Of the 876 patients, 165 (18.8%)
were included in the CLN-positive group and 711 (81.2%) in the CLN-negative group. All diagnosed
CLN metastases were microscopic metastases. We analyzed the clinicopathologic characteristics and
recurrence rates between the two groups.
4.3. Statistical Analysis
Statistical analysis was performed using SPSS Statistics for Windows, version 25.0 (IBM Co.,
Armonk, NY, USA). The Fisher’s exact test and Pearson’s chi-squared test were used for comparing
categorical variables. Continuous variables were compared with a Student’s t-test. A multivariate
Cox proportional hazards regression model was used to evaluate variables for the risk of recurrence.
DFS curves were constructed by the Kaplan–Meier method and compared using the log-rank test.
Cancers 2020, 12, 3032 9 of 12
5. Conclusions
PTMC patients who underwent thyroid lobectomy with prophylactic CCND and were diagnosed
as having pCLNM after surgery did not need to undergo completion total thyroidectomy. Due to the
possibility of lateral LN recurrence, active and frequent follow-up is necessary in PTMC with pCLNM.
Further research is needed on the effectiveness of prophylactic CCND for cN0 PTMC.
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